Butterfly Network, Inc. (BFLY)
USD 3.12
(-11.36%)
USD 3.12
(-11.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -145.61 Million USD | 34.91% |
| 2022 | -193.02 Million USD | -0.15% |
| 2021 | -192.72 Million USD | -19.25% |
| 2020 | -161.61 Million USD | -57.99% |
| 2019 | -102.29 Million USD | -92.7% |
| 2018 | -53.08 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -17.24 Million USD | -3.73% |
| 2024 Q1 | -21.26 Million USD | 54.19% |
| 2024 Q2 | -16.62 Million USD | 21.81% |
| 2023 Q1 | -35.04 Million USD | 28.48% |
| 2023 FY | -125.64 Million USD | 34.91% |
| 2023 Q3 | -32.56 Million USD | -4.15% |
| 2023 Q2 | -31.26 Million USD | 10.79% |
| 2023 Q4 | -46.41 Million USD | -42.54% |
| 2022 Q1 | -49.53 Million USD | -9.33% |
| 2022 Q2 | -48.45 Million USD | 2.18% |
| 2022 FY | -193.02 Million USD | -0.15% |
| 2022 Q4 | -49 Million USD | -6.45% |
| 2022 Q3 | -46.03 Million USD | 5.0% |
| 2021 Q2 | -36.68 Million USD | 31.74% |
| 2021 FY | -192.72 Million USD | -19.25% |
| 2021 Q4 | -45.3 Million USD | 20.5% |
| 2021 Q3 | -56.98 Million USD | -55.33% |
| 2021 Q1 | -53.74 Million USD | -141.99% |
| 2020 Q1 | -24.5 Million USD | 39.53% |
| 2020 Q4 | -22.21 Million USD | 75.81% |
| 2020 Q3 | -91.82 Million USD | -298.02% |
| 2020 Q2 | -23.07 Million USD | 5.87% |
| 2020 FY | -161.61 Million USD | -57.99% |
| 2019 FY | -102.29 Million USD | -92.7% |
| 2019 Q4 | -40.53 Million USD | 0.0% |
| 2018 FY | -53.08 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 102.248% |
| Allurion Technologies Inc. | -78.07 Million USD | -86.493% |
| Artivion, Inc. | 5.74 Million USD | 2635.876% |
| Avanos Medical, Inc. | 4.2 Million USD | 3566.905% |
| Butterfly Network, Inc. | -145.61 Million USD | -0.0% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 137.939% |
| Boston Scientific Corporation | 2.34 Billion USD | 106.215% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | -859.096% |
| CONMED Corporation | 130.78 Million USD | 211.335% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 109.492% |
| Paragon 28, Inc. | -37.3 Million USD | -290.281% |
| Glaukos Corporation | -128.7 Million USD | -13.139% |
| Globus Medical, Inc. | 133.14 Million USD | 209.364% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | -261.575% |
| Integer Holdings Corporation | 167.33 Million USD | 187.02% |
| Medtronic plc | 5.14 Billion USD | 102.831% |
| Nevro Corp. | -99.3 Million USD | -46.625% |
| Owlet, Inc. | -28.63 Million USD | -408.557% |
| Penumbra, Inc. | 73.55 Million USD | 297.971% |
| Vicarious Surgical Inc. | -80.66 Million USD | -80.51% |
| Smith & Nephew plc | 425 Million USD | 134.261% |
| Sonendo, Inc. | -57.74 Million USD | -152.169% |
| STERIS plc | 836.11 Million USD | 117.415% |
| Stryker Corporation | 3.88 Billion USD | 103.745% |
| Vapotherm, Inc. | -39.08 Million USD | -272.595% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 111.396% |